#EDEN Research – “US EPA registration for Mevalone Delta”, ramptastic!
- 2026-11-13 07:59:50
21 years after my last batch of lawyers letters from these scumbags and after several victories over them thanks to my good pals at the FRC, the battle goes on. A few weeks ago, I reported on Eden Biosolutions' (EDEN) piss poor results for the 15 months ended 31March 2026. One of the issues I highlighted was the sale by Eden ( formerly known as Eden Research) to its associated company TerpeneTech Limited of data access fees for £434,783. Terpenetech’s accounts are now out. GOTCHA!
Over the years I have reported Eden Research (EDEN) and some of the chancers who ran it to numerous regulators, including the FSA ( the equally useless forerunner of the FCA), AIM Regulation and the Financial Reporting Council. As a result of my efforts, The FSA did twice slam the former managers at Eden. The FRC has twice slammed the current managers at Eden. So, it is not pointless. I have written again
I showed in my expose yesterday that Eden Research (EDEN) had booked a significant sale of £434,783 representing over 10% of its revenues for the 15 months ended 31 March 2026 to a related party namely TerpeneTech which it classifies as an associate because it considers that it exerts significant influence over that entity. I also raised concerns about TerpeneTech’s ability to pay for that in light of almost continual losses in recent years and negative net current assets as shown in the Eden accounts. I have some very real concerns about the probity of this transaction. In this Note I look at guidance for auditors on the topic of fraud.
Twice in the past Eden Research (EDEN) has fooled investors by reporting bogus revenues with, now 29.99% thanks to a Panama pump fraud, owned Terpenetech. And the FRC has slated it for this. Guess what? It has done it again. I shall be contacting my good pals at the Financial Reporting Council once more!
Twice in recent years , the Finnacial Reporting Council has panned AIM listed perma dog Eden Research (EDEN), after complaints from me, about its dodgy accounts. And at the heart of those shambles was, since 2015, 29.9% owned associate Terpenetech. A trading update out yesterday shows Eden is at it again. This stinks.
My attention is brought to Eden Research (EDEN), one of the many companies to have sent me a menacing lawyer’s letter over the years, by news that its CFO Alex Abrey has made a share purchase. That in itself is a red flag for reasons I shall explain below but it got me digging away at Abrey’s CV.
Yesterday I gave a first review of the piss poor calendar 2024 results from Eden Research (EDEN), the 27th successive year of losses and cashburn. Now for a more detailed analysis which shows fundamental flaws which suggest this business will never generate cash and is thus utterly worthless
Reporting results for calendar 2024, the 27th year of operations, Eden Research (EDEN) has pulled off the usual stunt: sales up, operating losses up. The warning of what comes next is hidden in note 1.3 to the accounts
As it prepares for its 30th Birthday party this June, Eden Research (EDEN) must also be preparing for what it does best: another deeply discounted placing and with the fragrant Jo Hart at Midas no longer pumping the worthless shares with fanciful predictions this could be messy. No placing and a material uncertainty warning is a nailed on cert.
Founded just under 30 years ago and listed for almost a quarter of a century Eden Research (EDEN) battles with Blackbird (BIRD) for the title of AIM’s most jam tomorrow stock. Eden has only ever once turned an accounting profit for any half year and that was a result of a Panama Pump accounting fraud. It has now managed to send well over £40 million to money heaven, including the costs of sending me a stream of lawyers letters for exposing its naughtiness back in 2005. Today the snake in the garden of Eden speaks with a forked tongue as a new joint broker is appointed.







